“Research is to see what everybody else has seen, and think what nobody has thought.”

-Dr. Albert Szent-Györgyi, MD, PhD de Nagyrápolt – 1937 winner of the Nobel Prize in Physiology or Medicine

Through the leadership and drive of Rebecca Lambert, NED Biosystems founder, and our expert team of scientists, NED’s approach is to find solutions that have yet to be imagined.

Our Mission and Principles

Our mission is to provide uncommon therapies so patients achieve and sustain “No Evidence of Disease.” Uncommon therapies are those that lack customary toxicity and side effects and allow patients to live life fully, and are those suitable for patients globally, including areas of the world plagued by health disparities.

We are driven by our guiding principles:

  • We work to the essential needs of patients and their families;
  • Integrity is woven into everything that we do;
  • Our therapies are scientifically grounded optimal solutions driven by continuous attention to new research findings;
  • We believe in the body’s innate ability to re-learn health;
  • We commit to challenge what “cannot be done”.

The Journey Begins

In 2001, NED founder Rebecca Lambert’s sister, Renée, was diagnosed with stage IV leiomyosarcoma (LMS), just 18 months after giving birth to a beautiful baby boy. LMS is a particularly deadly sarcoma, a rare type of cancer. Renée was given less than one year to live and “not a pretty one”. Rebecca became determined to develop a treatment that would permit her sister to spend more time with her son and that each day would be one with full quality of life.

Working with leading cancer researchers throughout the country, Rebecca assembled a research-based, repurposed, multi-faceted treatment approach, analyzing the pathways that initiate and drive disease. Harvard’s Dr. Judah Folkman, a pioneer in “angiogenesis” (new blood vessel formation research) became her mentor. By taking a combination of well-reported oral agents, which successfully affect disease pathways, Renée lived for nine additional years. Maintaining her quality of life, Renée was also able to raise her son.

Shortly before Renée’s passing, Rebecca founded NED Biosystems, Inc. NED-170 CANCER, the company’s cancer treatment, has its roots in the early research conducted for her sister. This translational approach has been rapidly applied by a team of scientists to the development of NED’s treatment approach for COVID-19.

Core Management and Key Advisors

Board of Directors

Scientific Advisory Board – Oncology

Strategic Advisors

Christine Davis
Caitlin Donohue
Jean Hamilton
Debra McDowell
Gale Pollock, CRNA, FACHE, FAAN, Maj. Gen. (Ret)
Randy Slack
John Warden, III, Col. (Ret)
Diane Whitty

Lead Investors

First Round Capital – Series A Lead Investor
Benjamin H. Griswold, IV – Series B Lead Investor